Capital Expenditures for AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current capital expenditures (TTM) is $4.09B USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AZN
Currently viewingCapital ExpendituresSwitch metric
Latest period
$4.09B
YoY change
-38.7%
5Y CAGR
+1.5%
Peak year (2012)
$4.62B
Cumulative capital expenditures
$67.63B
CapEx history chart for AstraZeneca (AZN) from 1990 to 2025
CapEx history table for AstraZeneca (AZN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $2.81B | -38.7% | ||
| 2024 | $4.59B | +21.4% | ||
| 2023 | $3.78B | +46.9% | ||
| 2022 | $2.57B | +16.9% | ||
| 2021 | $2.20B | -15.6% | ||
| 2020 | $2.61B | +5.9% | ||
| 2019 | $2.46B | +79.4% | ||
| 2018 | $1.37B | -15.4% | ||
| 2017 | $1.62B | -30.0% | ||
| 2016 | $2.31B | -17.0% | ||
| 2015 | $2.79B | +1.3% | ||
| 2014 | $2.75B | +33.7% | ||
| 2013 | $2.06B | -55.4% | ||
| 2012 | $4.62B | +256.1% | ||
| 2011 | $1.30B | -46.4% | ||
| 2010 | $2.42B | -18.2% | ||
| 2009 | $2.96B | -26.8% | ||
| 2008 | $4.04B | +140.6% | ||
| 2007 | $1.68B | +25.4% | ||
| 2006 | $1.34B | +36.8% | ||
| 2005 | $979.00M | +194.9% | ||
| 2004 | $332.00M | -74.1% | ||
| 2003 | $1.28B | -4.3% | ||
| 2002 | $1.34B | -40.8% | ||
| 2001 | $2.26B | +54.9% | ||
| 2000 | $1.46B | -46.9% | ||
| 1999 | $2.75B | +225.7% | ||
| 1998 | $844.88M | +11.8% | ||
| 1997 | $755.47M | +18.3% | ||
| 1996 | $638.76M | +48.2% | ||
| 1995 | $431.11M | -12.5% | ||
| 1994 | $492.47M | +6.4% | ||
| 1993 | $462.99M | +13.9% | ||
| 1992 | $406.47M | +5.5% | ||
| 1991 | $385.46M | -28.6% | ||
| 1990 | $540.10M | — |
CapEx values are taken from AstraZeneca's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of AstraZeneca (AZN) capital expenditures is $2.81B – plunged 38.7% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca capital expenditures compounded at +1.5% per year, with the latest reading among the more recent periods of the dataset.
AstraZeneca capital expenditures peaked at $4.62B in 2012; the latest annual figure is $2.81B in 2025 (39.2% below peak).
2012 marks the peak capital expenditures at $4.62B, with the historical low of $332.00M recorded in 2004.
Within Healthcare, AstraZeneca (AZN) ranks 6th among 8 peers we track. The peer median for capital expenditures is $3.87B.
AstraZeneca Capital Expenditures by Year
AstraZeneca Capital Expenditures 2025: $2.81B
AstraZeneca capital expenditures in 2025 was $2.81B, plunged 38.7% below 2024.
AstraZeneca Capital Expenditures 2024: $4.59B
AstraZeneca capital expenditures in 2024 was $4.59B, grew 21.4% from 2023.
AstraZeneca Capital Expenditures 2023: $3.78B
AstraZeneca capital expenditures in 2023 was $3.78B, surged 46.9% from 2022.
AstraZeneca Capital Expenditures 2022: $2.57B
AstraZeneca capital expenditures in 2022 was $2.57B, grew 16.9% from 2021.
AstraZeneca Capital Expenditures 2021: $2.20B
AstraZeneca capital expenditures in 2021 was $2.20B.
See more financial history for AstraZeneca (AZN).
Sector peers — CapEx
Companies in the same sector as AstraZeneca, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $1.52B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is AstraZeneca's capital expenditures?
- Latest reported capital expenditures for AstraZeneca (AZN) is $4.09B (period ending December 31, 2025).
How has AstraZeneca capital expenditures changed year-over-year?
- AstraZeneca (AZN) capital expenditures changed -38.7% year-over-year on the latest annual filing.
What is the long-term growth rate of AstraZeneca capital expenditures?
- AstraZeneca (AZN) capital expenditures compound annual growth rate is +1.5% over the most recent 5 years available.
When did AstraZeneca capital expenditures hit its highest annual value?
- AstraZeneca capital expenditures reached its highest annual value of $4.62B in 2012.
What was AstraZeneca capital expenditures in 2024?
- AstraZeneca (AZN) capital expenditures in 2024 was $4.59B.
What was AstraZeneca capital expenditures in 2025?
- AstraZeneca (AZN) capital expenditures in 2025 was $2.81B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,863 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $324.23 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $58.74B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Buybacks
0.16% TTM buyback yield. Shareholder yield & SBC comparison.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.73%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.